MARKET NEWS

Sandoz & Teva Have Potential to Transform Epinephrine Injection Market
Inoviem Scientific Enters Into Service-Based Partnership With XoNovo
Opiant Pharmaceuticals Announces Final Patient Enrolled in Phase 2 Clinical Trial
Pieris Pharmaceuticals Announces Dosing of First Patient in Phase I Combination Trial
MilliporeSigma Launches Next-Generation Process Technologies for Intensified Drug Production
Aucta Pharmaceuticals Signs Commercial Manufacturing Agreement With Catalent  

  FEATURED EDITORIAL

  COMPANY PROFILE

 

 

Enable Injections’ technology is designed to meet the delivery needs of biologics treatments that comprise an increasing focus in product development. The Enable Injections enFuse (wearable infuser) can address the new set of challenges and deliver these high-volume, often highly viscous therapeutics to the patient in an effective, safe, and affordable means that cannot be addressed by legacy injection systems. Enable Injections is introducing their wearable infusers to deliver these drugs subcutaneously, by patients at home, with the potential to help revolutionize treatment of cancer, autoimmune deficiencies, blood disorders, and a range of other conditions. Enable Injections intends to create market-leading biologics delivery devices to support patient-centric self-administration. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Biothera Pharmaceuticals Announces Immuno-Oncology Clinical Trial Collaboration With AstraZeneca

Biothera Pharmaceuticals Announces Immuno-Oncology Clinical Trial Collaboration With AstraZeneca

Biothera Pharmaceuticals, Inc. recently announced a clinical collaboration with AstraZeneca to evaluate whether the combination of Biothera’s Imprime PGG and AstraZeneca’s durvalumab (IMFINZI) can decrease tumor volume in patients with primary untreated locally advanced head and neck cancer prior to surgical resection.

Metrion Biosciences & AMRI Collaborate to Offer Ion Channel Drug Discovery Services

Metrion Biosciences & AMRI Collaborate to Offer Ion Channel Drug Discovery Services

Metrion Biosciences Limited and AMRI recently announced they have signed a new collaboration agreement. The alliance will promote Metrion’s electrophysiology and ion channel screening expertise to global pharmaceutical and biotechnology clients.

CURE Pharmaceutical Expands Distribution of  CUREfilm Technology With First Licensing Agreement

CURE Pharmaceutical Expands Distribution of  CUREfilm Technology With First Licensing Agreement

CURE Pharmaceutical recently announced it entered into a multi-year licensing agreement for the first time with a leading international cannabis company.

Reata Announces Receipt of -Million Milestone Payment

Reata Announces Receipt of $30-Million Milestone Payment

Reata Pharmaceuticals, Inc. recently announced it has received a $30-million milestone payment from its licensee, Kyowa Hakko Kirin Co., Ltd. following the initiation of AYAME, a Phase 3 clinical trial to assess the efficacy and safety of bardoxolone methyl (bardoxolone) for the treatment of diabetic kidney disease in Japan.

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

September 19 – Lyophilization Manufacturing
September 26 – Excipients